Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: IQBAL LATIF who wrote (29701)	11/12/1999 10:36:00 AM
From: the options strategist	Respond to of 50167

AMD: We will retake chip speed crown By Michael Kanellos and Stephen Shankland Staff Writers, CNET News.com November 11, 1999, 3:50 p.m. PT update SUNNYVALE, California--AMD will regain the speed crown from rival chipmaker Intel with 750-MHz Athlon chips later this year and follow it up with a raft of speedier chips in 2000, AMD's chief executive said today amid a sudden wave of optimism for the often troubled company. The cavalcade of chips was announced today at a relatively upbeat AMD analyst's meeting at the company's headquarters here. Revenues will be above $800 million, stronger than expected for the fourth quarter, CEO Jerry Sanders and other executives said, on the strength of its microprocessor sales and sales of flash memory. Break-even for the company is $850 million, executives said. At one point during the meeting, Sanders announced that the SEC temporarily halted trading because of the new positive picture. After the halt, AMD shares jumped 5.19 to close at 28.19 "The 750-MHz Athlon systems should be available from top-tier [computer] makers] by year's end, a quarter ahead of schedule," Sanders said. "There is no question we are moving up the food chain. We're experiencing a strong quarter. Demand for all our products is robust."

To: IQBAL LATIF who wrote (29701)	11/12/1999 10:53:00 AM
From: the options strategist	Read Replies (1) \| Respond to of 50167

IQ, what are your current objectives re: indicators? Thanks. jj

To: IQBAL LATIF who wrote (29701)	11/12/1999 11:17:00 AM
From: James C. Mc Gowan	Respond to of 50167

Hello IKE: thanks for posting the article re: Elan Pharm. This has long been a favorite of mine, since I visited the headquarters in Ireland 4 years ago. There have been minor missteps, including a spurious accounting issue, which allowed the shorts to take this issue down last year, and ended up with a few pennies restatement. Now, as indicated in the article you posted, the big scare is a delay in introduction of a minor drug in Elan's pipeline. I believe this company represents tremendous value at this price, with a strong pipeline of pain/neurological disorder treatments to be released in the next year, combined with leading Alzheimer's research. Human trials applications are being reviewed at this time by FDA, so that work can commence very soon. Oh, BTW, this company makes a lot of money now, but this has been overlooked by Wall Street, and the company is shunned. It will see brighter days, for the patient investor. Regards, James